The LAG3 protein belongs to the Ig superfamily and contains 4 extracellular Ig-like domains (D1-D4). This molecule plays an key role in the immune response through negative regulation of T-cell proliferation, function, and homeostasis. It is required for maximum natural and induced regulatory T-cell function. LAG3 is closely related to the T-cell co-receptor CD4, and like CD4, binds to MHC class II molecules – but with a significantly higher affinity. It is expressed exclusively in activated T- and natural killer (NK) lymphocytes.
Studies with the LAG3 antibody from Baixeras’ lab established LAG3 as a new human leukocyte antigen class II antigen ligand1. More detailed characterization studies relied upon use of the LAG3 antibody to map critical functional domains within the various Ig-like areas2. Follow-up studies out of the same lab employed yet again the LAG3 antibody to generate expression profiles of infiltrating T-lymphocytes (TILs)3. Their data suggests that TIL-expressed LAG3 is involved in class II engagement on antigen presenting cells (APCs), APC activation, and Th1/Tc1 cell commitment. Di Carlo’s group also compared the role of LAG3 versus IL12 in promoting intratumor recruitment, activation, and Th1 APC commitment using the LAG3 antibody4. Some intriguing findings out of Triebel’s lab indicate that soluble LAG3 (sLAG3) could serve as a valuable prognostic marker for particular subsets of breast cancer, and emphasize the importance of Th1 response in adjuvant therapy response. Use of the LAG3 antibody allowed these researchers to carefully profile a cohort of 246 breast cancer patient seras with regards to their estrogen and progesterone receptor expression state5.
Novus Biologicals offers Lymphocyte activation gene 3 reagents for your research needs including:
- Lymphocyte activation gene 3 antibodies
- Lymphocyte activation gene 3 lysates
- Lymphocyte activation gene 3 peptides and proteins